CommercialPrior AuthMedium impact
Cystic Fibrosis
Blue Cross & Blue Shield of Mississippi·MS · Pulmonology, Pediatrics·Medical Policy
We identified it
Jun 20, 2026
Summary
This BCBS Mississippi policy establishes prior authorization requirements for all cystic fibrosis CFTR modulator medications (Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek). Alyftrek is specifically considered not medically necessary as other covered options exist. All requests require genetic testing confirmation and specialist prescribing.
Action Required
Immediately: Billing team must ensure prior authorization is obtained for all cystic fibrosis CFTR modulator medications (Kalydeco, Orkambi, Symdeko, Trikafta) before prescribing. Verify patient age requirements, genetic testing documentation, and specialist prescriber involvement. Do not submit claims for Alyftrek as it is considered not medically necessary. Claims without prior authorization will be denied.